Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Epcoritamab by Genmab for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
Epcoritamab by Genmab for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to...
Epcoritamab by Genmab for Burkitt Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I...
Epcoritamab by Genmab for Non-Hodgkin Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...
Epcoritamab by Genmab for Mantle Cell Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
Epcoritamab by Genmab for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...